Integrated Renal Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.31 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.17 Cr
as on 24-10-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 430.37%
(FY 2023)
- Profit -294.82%
(FY 2023)
- Ebitda -509.98%
(FY 2023)
- Net Worth 47.88%
(FY 2023)
- Total Assets 47.83%
(FY 2023)
About Integrated Renal Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.31 Cr and a paid-up capital of Rs 1.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikas Verma, Rakesh Thakur, Mayank Sharma, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999DL2018PTC331039
- Company No.
331039
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2018
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Integrated Renal Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Verma  | Director | 25-May-2021 | Current |
| Rakesh Thakur | Director | 16-Mar-2018 | Current |
| Mayank Sharma | Director | 25-May-2021 | Current |
Ashish Tyagi  | Director | 12-Jun-2018 | Current |
Financial Performance and Corporate Structure Insights of Integrated Renal Sciences.
Integrated Renal Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 430.37% increase. The company also saw a substantial fall in profitability, with a 294.82% decrease in profit. The company's net worth Soared by an impressive increase of 47.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Integrated Renal Sciences?
In 2023, Integrated Renal Sciences had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
7 Med India Private LimitedActive 11 years 11 daysVikas Verma, Rakesh Thakur and 2 more are mutual person
Integrated Kidney Solutions Private LimitedActive 4 years 10 monthsVikas Verma, Rakesh Thakur and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Integrated Renal Sciences?
Unlock and access historical data on people associated with Integrated Renal Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Integrated Renal Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Integrated Renal Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
